Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).-Reference-Cited by-同舟云学术

Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

Published:2016-05-20 Issue:15_suppl Volume:34 Page:7503-7503
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Rummel Mathias J.¹,Knauf Wolfgang²,Goerner Martin³,Soeling Ulrike⁴,Lange Elisabeth⁵,Hertenstein Bernd⁶,Eggert Jochen⁷,Schliesser Georg C⁸,Weide Rudolf⁹,Blumenstengel Klaus¹⁰,Detlefsen Ninia¹¹,Hinke Axel¹²,Kauff Frank¹,Barth Juergen¹

Affiliation:

1. Universitaetsklinik, Giessen, Germany;

2. Centre for Haematology & Oncology Bethanien, Berlin, Germany;

3. Stadt Klinikum Bielefeld, Bielefeld, Germany;

4. Onkologie Kassel, Kassel, Germany;

5. Evangelisches Krankenhaus Hamm, Hamm, Germany;

6. Department of Hematology and Oncology, Klinikum Bremen Mitte, Bremen, Germany;

7. Onkologische Praxis Moers, Moers, Germany;

8. Medical Office, Giessen, Germany;

9. Hematology and Oncology Group Practice, Koblenz, Germany;

10. Medical Practice for Oncology and Hematology, Eisenach, Germany;

11. Universitaetsklinikum, Giessen, Germany;